NasdaqGM:HROWPharmaceuticals
Record 2025 Results And Boosted Investment Could Be A Game Changer For Harrow (HROW)
In early 2026, Harrow reported record Q4 and FY2025 results with strong revenue growth and a shift to positive operating cash flow, but also missed EBITDA and EPS expectations because of a one-time R&D charge and higher commercial spending.
Management tempered its 2026 guidance while accelerating investment behind products such as VEVYE, TRIESENCE, BYOOVIZ, and BYQLOVI, signaling a deliberate trade-off between near-term profitability and building a broader ophthalmic portfolio.
We’ll now...